<DOC>
	<DOCNO>NCT00315835</DOCNO>
	<brief_summary>The objective study assess safety buprenorphine transdermal system ( 5 , 10 , 20 mg ) comparison placebo transdermal system subject moderate severe pain orthopedic surgery . The double-blind treatment intervention duration 72 hour time supplemental analgesic medication ( intravenous morphine PCA ) provide subject addition study drug .</brief_summary>
	<brief_title>Safety Buprenorphine Transdermal Delivery System Subjects With Mod-to-Sev Pain Following Orthopedic Surgery .</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic twenty-five year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain . Transdermal system may offer advantage currently indicate oral product include ease convenience use , improve compliance , possible reduction patient care , prolong consistent delivery drug .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>underwent major orthopedic surgical procedure require general anesthesia , expect hospitalized &gt; /=4 day postoperatively . moderate great pain postrecovery anesthesia expect , great , moderate pain , without analgesic , &gt; /=4 day postsurgery . receive chronic opioid therapy preoperatively &gt; 1 month total daily dose &gt; /= 60 mg oral morphine equivalent . significant concurrent pulmonary condition . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>postoperative pain</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
</DOC>